ABSTRACT OBJECTIVES This study evaluated the tolerability and feasibility of titration of 2 distinctly acting beta-blockers (BB) in elderly heart failure patients with preserved (HFpEF) and reduced (HFrEF) left ventricular ejection fraction.
C hronic heart failure (HF) continues to be a major health problem in the community (1) . Nearly half of HF patients have preserved left ventricular ejection fraction (HFpEF) (2) , and the prevalence of HFpEF patients is increasing (3) .
Recent data suggest that mortality and readmission rates in HFpEF are higher than described and that the overall prognosis is comparable to HFrEF (2, 3) . Furthermore, although survival rates of HFrEF patients improved over the past decades, mortality remains unchanged in HFpEF patients (3) .
The diverging mortality trend reflects a lack of treatments with proven survival benefit for HFpEF, resulting partially, from the scarcity of large clinical trials in this condition (4) .
Robust evidence supports the use of beta-blockers (BB) in HFrEF, although their use in HFpEF remains controversial (5) . BBs could theoretically be useful and recommended by guidelines to control HR in HFpEF (e.g., by lowering blood pressure [BP] and/or afterload, reducing left ventricular hypertrophy, lengthening diastolic filling time, and reducing high ventricular rates, which are poorly tolerated in this condition) (6) . They also reduce the risk of ventricular arrhythmias, which are one of the most common modes of death in HFpEF (7) . Registry data, 1 small randomized, controlled trial, and the large SENIOR study, have suggested a prognostic benefit due to beta-blockade in HFpEF (8) (9) (10) . SENIOR study, however, using only a left ventricular ejection fraction (LVEF) cutoff value of >35% for the definition of HFpEF, has been criticized (9) . On the other hand, the
OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart
Failure) registry showed that the use of BBs in HFpEF patients was be related to poor outcomes (11) , and another small observational study suggested that BB therapy may lead to a higher risk of rehospitalization in women with HFpEF (12) . However, little is still known about the tolerability of BBs in HFpEF. Although the overall tolerability of nebivolol was found to be similar for both HFrEF and HFpEF in the SENIOR study, prescription of BBs in both conditions remains low despite evidence of their prognostic benefit in HFrEF (13) . The main results
from the CIBIS-ELD (Cardiac Insufficiency Bisoprolol
Study in Elderly) trial suggest that there is no difference in achieved doses and tolerability to target doses between bisoprolol and carvedilol in elderly HF patients (14) . Although BBs are currently indicated to treat comorbidities associated with HFpEF, there are no recommendations of how to initiate BB treatment in HFpEF (15) . Also according to the primary objective of the CIBIS-ELD trial, which addressed the superiority of bisoprolol versus carvedilol, in this prespecified analysis, we therefore compared the tolerability and clinical effectiveness of these 2 differentially acting BBs on the burden of symptoms, functional capacity, and echocardiographic assessment of systolic and diastolic myocardial function in elderly HFrEF and HFpEF patients (16) .
METHODS
TRIAL DESIGN AND PATIENTS. Details of the CIBIS-ELD trial design have been published previously (16) . This investigator-initiated, randomized, doubleblind, double-dummy, parallel group trial was performed in Germany, Montenegro, Serbia, and Slovenia. Patients eligible for inclusion were adults 65 years or older with symptomatic chronic HF consistent with NYHA functional class $II at presentation and either a reduced LVEF #45% (HFrEF patients) or a preserved ejection fraction (LVEF > 45%) (HFpEF patients), with evidence of diastolic dysfunction as defined below. At baseline, eligible participants had to be BB naïve or currently taking #25% of the recommended BB dose for HFrEF (#2.5 mg once daily for bisoprolol; #6.25 mg twice daily for carvedilol). They had to be clinically stable with no changes in HF medication for at least 2 weeks before randomization.
Major exclusion criteria were known contraindications to BB treatment such as hypotension with a resting systolic BP < 90 mm Hg, severe pulmonary disease or severe asthma, bradycardia with a resting HR < 55 beats/min before commencement of therapy, second or third degree sinoatrial block (without pacemaker) and known sick sinus syndrome. This is a pre-specified subgroup analysis of the differences between HFpEF and HFrEF in the CIBIS-ELD trial, which tested whether the target dose could be reached more often with bisoprolol than with carvedilol (14, 16) . Tolerability and clinical effectiveness of bisoprolol versus that of carvedilol on the burden of symptoms, functional capacity, and echocardiographic assessment of systolic and diastolic myocardial function in elderly HFrEF and HFpEF patients were compared. Tolerability was defined as tolerance (yes/no) of the study medication target dose as per cardiology guidelines recommended (primary endpoint). Further endpoints were time to treatment failure, % of target dose for long term treatment, number of adverse events or serious adverse events (14, 16) .
The protocol and amendments were approved by all responsible national institutes for drugs and 
Beta-Blocker Titration in HFpEF vs. investigators were allowed to delay dose titration, reduce the dose or discontinue the study treatment.
The titration phase was followed by a 4-week maintenance period. The final visit was conducted at 10 weeks (or 12 weeks for patients weighing >85 kg).
Delayed up-titration to the target dose was any titration that did not follow the titration scheme (i.e.
an up-titration step was postponed to the next visit, or the study medication was even temporarily downtitrated), but eventually, the target dose was reached after 3 months.
LABORATORY MEASUREMENTS. At baseline and at 12 weeks, blood samples were taken in standardized conditions by venous puncture after a 20-minute supine resting period. All samples were immediately centrifuged and stored below À80 C.
N-terminal pro-B-type natriuretic peptide (NTproBNP) was analyzed using a commercially avail- Kendall's tau for each of the functional groups separately, and the tau coefficients were compared between groups using the Gauss approximation test.
Analyses were performed using SPSS version 15 software (SPSS Inc., Chicago, Illinois). The first and corresponding authors had final responsibility for the decision to submit the paper for publication. bisoprolol. Baseline characteristics are shown in Table 1 . HFpEF patients were more frequently female and tended to be older, with greater body mass index (BMI), higher systolic BP and lower resting
RESULTS
Edelmann et al. 
Beta HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced ejection fraction.
Edelmann et al. the primary endpoint defined as titration to the target dose without delay, although in both groups, 31% of the patients finally reached the target dose. This implies that it might take more time to titrate HFpEF patients on a BB dose than HFrEF patients. As there is no exact definition of "tolerability," one could discuss whether it is more important to reach a target dose rather than reach it without any delay.
We found no differences between the probabilities of HFpEF and HFrEF patients reaching the target dose, but HFpEF patients experienced more titration delays and more adverse events.
Both BBs were comparable regarding their tolerability and clinical effectiveness in HFrEF and HFpEF.
Reduction of HR and BP was greater in HFpEF patients than in HFrEF patients, which is in concordance with previously published results (21) . This The severity of diastolic dysfunction is related to the functional capacity of HFpEF patients (26) ; thus an improvement of these properties is considered an appropriate target. Impaired relaxation and diastolic left ventricular filling, which are pathophysiological
Beta-Blocker Titration in HFpEF vs. HFrEF (29) . However, despite no effect on E/E 0 or LAVI in our study, NT-proBNP increased in HFpEF after BB titration, which rather indicates a worsening of left ventricular filling pressure.
Also the presence of the BB-related induction of chronotropic incompetence (CTI) is known to be a major contributor to exercise intolerance in this condition, might have influenced our results. CTI affects 25% to 30% of all HFpEF patients according to certain studies (27, 30) , whereas others show that the prevalence can be as high as 57% (31) . Autonomic dysfunction is a main contributing factor to CTI (32), which is more common in patients receiving BBs (32).
However, CTI was not investigated in our trial, wherefore only assumptions on the potential impact of CTI can be made. 
